Novartis India Ltd Hits Intraday Low Amid Price Pressure on 16 Sep 2026

Intraday Performance and Price Movement

On 16 Sep 2026, Novartis India Ltd’s share price fell by 7.96% on the day, closing near its lowest point of Rs 1,992.8. This intraday low represents a significant deviation from the stock’s recent trading range and highlights the immediate selling pressure faced by the company’s shares. The stock’s weighted average price volatility stood at 5.87%, underscoring the heightened fluctuations throughout the trading session.

The stock’s performance today was markedly weaker than the Pharmaceuticals & Biotechnology sector, underperforming by 6.96%. This divergence indicates that while the sector may have experienced some resilience, Novartis India Ltd’s shares faced disproportionate downward pressure.

Recent Trend and Moving Averages

Novartis India Ltd has been on a declining trajectory for the past three consecutive trading days, accumulating a loss of 16.42% over this period. Despite this short-term weakness, the stock remains above its 20-day, 50-day, 100-day, and 200-day moving averages, signalling that longer-term technical support levels have not yet been breached. However, the share price is currently trading below its 5-day moving average, reflecting immediate short-term weakness and a potential shift in momentum.

This technical setup suggests that while the stock has maintained strength over the medium to long term, the recent price action indicates a cautious near-term outlook among market participants.

Market Context and Broader Indices

While Novartis India Ltd faced selling pressure, the broader market showed mixed signals. The Sensex opened 245.49 points higher and was trading at 74,391.02, up 0.52% at the time of reporting. Despite this positive intraday movement, the Sensex remains 3.82% above its 52-week low of 71,545.81 and has been on a three-week losing streak, declining by 3.72% over that period.

Technical indicators for the Sensex reveal a bearish setup, with the index trading below its 50-day moving average, which itself is positioned below the 200-day moving average. This configuration often signals caution among investors and suggests that the market is navigating a period of uncertainty.

Notably, mega-cap stocks have been leading the market gains today, contrasting with the small-cap segment where Novartis India Ltd is classified. This divergence may contribute to the stock’s relative underperformance.

Comparative Performance Metrics

Examining Novartis India Ltd’s performance across various time frames highlights a complex picture. The stock’s one-day return of -7.78% contrasts sharply with the Sensex’s 0.54% gain on the same day. Over the past week, the stock declined by 7.71%, while the Sensex fell by a more modest 0.48%.

However, over longer periods, Novartis India Ltd has demonstrated robust gains. The one-month return stands at 27.26%, three-month at 52.81%, and one-year at 123.90%, significantly outperforming the Sensex’s negative returns over these intervals. Year-to-date, the stock has surged 159.20%, compared to the Sensex’s decline of 12.69%. Even over three, five, and ten-year horizons, Novartis India Ltd has outpaced the benchmark index, reflecting strong historical growth despite recent volatility.

Technical Indicators and Momentum

Technical analysis presents a mixed but predominantly positive medium-term outlook for Novartis India Ltd. The Moving Average Convergence Divergence (MACD) indicator is bullish on both weekly and monthly charts, suggesting underlying momentum remains supportive. Bollinger Bands also indicate mild bullishness weekly and bullishness monthly, implying the stock is trading within a favourable volatility range.

Conversely, the Relative Strength Index (RSI) shows no clear signal on a weekly basis but registers bearish tendencies monthly, indicating some caution in momentum strength. The Know Sure Thing (KST) indicator is mildly bearish weekly but bullish monthly, further reflecting short-term uncertainty amid longer-term strength.

Other indicators such as Dow Theory and On-Balance Volume (OBV) show no definitive weekly trend but maintain bullish signals monthly, reinforcing the notion that the recent price weakness may be a short-term correction within a broader positive trend.

Mojo Score and Rating Update

Novartis India Ltd holds a Mojo Score of 71.0, reflecting a positive overall assessment of the company’s financial and market metrics. The stock’s Mojo Grade was upgraded from Hold to Buy on 8 Sep 2026, signalling improved confidence in its medium-term prospects. Despite today’s price pressure, this rating upgrade indicates that the company’s fundamentals and technical outlook remain favourable.

The stock is classified as a small-cap within the Pharmaceuticals & Biotechnology sector, which often entails higher volatility and sensitivity to market fluctuations compared to larger-cap peers. This classification aligns with the observed price swings and relative underperformance during volatile market conditions.

Summary of Price Pressure and Market Sentiment

In summary, Novartis India Ltd’s decline to an intraday low of Rs 1,992.8 reflects immediate selling pressure amid a volatile trading environment. The stock’s underperformance relative to its sector and the broader market, combined with its recent three-day losing streak, highlights short-term caution among traders. However, the stock’s position above key longer-term moving averages and its positive medium-term technical indicators suggest that this weakness may be a temporary phase within a broader uptrend.

Market sentiment remains mixed, with the Sensex showing modest gains led by mega-cap stocks, while small-cap stocks like Novartis India Ltd face greater headwinds. Investors and analysts will likely continue to monitor the stock’s price action closely in the coming sessions to assess whether the current pressure persists or stabilises.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →